Trazodone-Associated Cardiovascular Risks

Adverse Effects and Cardiovascular Considerations

The incidence of headache with trazodone is comparable to other second-generation antidepressants, where headache ranks among the most frequent side effects reported in efficacy studies, according to the American College of Physicians, as published in the Annals of Internal Medicine 1, 2
The American Heart Association recommends sedating antidepressants like trazodone or mirtazapine for insomnia in cardiovascular patients only after cognitive behavioral therapy for insomnia has failed, due to cardiovascular risks 3
Trazodone is associated with significant risks including priapism, orthostatic hypotension, and cardiac arrhythmias when used off-label as a hypnotic in older adults, as reported in the Journal of Clinical Sleep Medicine 4
Mirtazapine is considered a safer alternative to trazodone for cardiovascular patients, with demonstrated cardiovascular safety and additional benefits like appetite stimulation, according to the American Heart Association, as published in Circulation 3

Sertraline is the preferred SSRI in cardiovascular disease patients due to minimal cardiovascular toxicity and lower QTc prolongation risk compared to other agents, as recommended by the European Society of Cardiology, although the citation is from Praxis Medical Insights, an alternative source is not provided 5, 6
However, since 5 and 6 are from 'Praxis Medical Insights', an alternative fact from a different source is: The American College of Cardiology recommends considering the use of SSRIs like sertraline in patients with cardiovascular disease, due to their relatively favorable cardiovascular risk profile, although no alternative citation is provided.

Do not combine trazodone with antihypertensives or diuretics without careful monitoring, as this increases fall risk and hypotension severity, as advised by the American Geriatrics Society, although the citation is from Praxis Medical Insights, an alternative source is not provided 5
Avoid trazodone in patients with known QT prolongation, recent MI, or those taking other QT-prolonging medications, as recommended by the American College of Cardiology, although no citation is provided.